The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
WCLC 2022 | The impact of baseline clinicopathologic genomic features on outcomes of KRASG12Ci in NSCLC
Giuseppe Lamberti, MD, University Hospital of Bologna, Bologna, Italy, shares insight on data collected on patients with KRASG12C non-small cell lung cancer (NSCLC) who received the KRASG12C inhibitors sotorasib or adegrasib as a single agent. Clinicopathologic and genomic features of the tumors were collected by either plasma or tumor next-generation sequencing wand were correlated with overall response rate (ORR), progression-free survival (PFS) and overall-survival (OS). Performance status and later treatments lines were found to be associated with worse prognosis. Additionally, STK11 co-mutations and CDKN2A deficiency were associated with worse PFS. This interview took place at the IASLC 2022 World Conference on Lung Cancer congress in Vienna, Austria.
![Impact of [18F]FDG PET/CT-derived metabolic parameters on outcomes in extensive-stage SCLC](https://i.ytimg.com/vi/soBIdqv8jvQ/mqdefault.jpg)
